FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2324254509> ?p ?o ?g. }

• W2324254509 endingPage "7076" @default.
• W2324254509 startingPage "7076" @default.
• W2324254509 abstract "7076 Background: Chronic lymphocytic leukemia (CLL) is the most common form of leukemia in the Western Hemisphere, with over 10,000 cases diagnosed annually in the United States. It is characterized by progressive accumulation of functionally incompetent long-lived lymphocytes, shown to be secondary to a defect in programmed cell death or apoptosis. The phosphodiesterase inhibitor sildenafil induces capsase dependent apoptosis of malignant B lymphocytes in vitro. This study will test the hypothesis that sildenafil reduces the expression of BCL-2 and increases the spontaneous apoptosis rate of malignant B-cells in patients with CLL. Methods: Thirteen patients with Rai Stage 0 CLL were enrolled. Nine of the patients were aged sixty-five years or older and received sildenafil 25 mg weekly; four patients were under the age of sixty-five and received sildenafil 25 mg weekly. All patients took the medication for a total of three months. Lymphocyte counts, BCL-2 expression, caspase 3 activity, and apoptosis rate were monitored on enrollment and monthly for duration of the study. Results: The median age of patients enrolled in the study was 74 with a median white blood cell count of 18 x10 3 /mL. Twelve of the 13 patients completed three months of therapy. While one patient withdrew due to blehparitis, not felt to be a side effect of sildenafil, all other patients tolerated the medication well without any adverse effects. There was no significant decrease in white blood cell count or Bcl-2 expression; capsase 3 activity and apoptosis rates remained undetectable on presentation and throughout treatment. Conclusions: At a dose of 25 to 50 mg weekly, sildenafil does not appear to have any effects on the malignant B cells in CLL. While this dose may not produce a measurable clinical or cellular response, higher doses may still have an effect on the malignant B cells of CLL. The dose of sildenafil was based on a case series of patients with Viagra who had decreases in IgM levels while taking sildenafil 25–50 mg weekly. Subsequent studies in have shown a greater reduction in IgM in patients taking sildenafil 100 mg daily and patients did not report any significant side effects. A follow-up study using sildenafil 100 mg daily is warranted. No significant financial relationships to disclose." @default.
• W2324254509 created "2016-06-24" @default.
• W2324254509 creator A5016124900 @default.
• W2324254509 creator A5021513092 @default.
• W2324254509 creator A5026444533 @default.
• W2324254509 creator A5045568688 @default.
• W2324254509 date "2009-05-20" @default.
• W2324254509 modified "2023-09-27" @default.
• W2324254509 title "The effects of sildenafil citrate on malignant B-cells in patients with chronic lymphocytic leukemia" @default.
• W2324254509 doi "https://doi.org/10.1200/jco.2009.27.15_suppl.7076" @default.
• W2324254509 hasPublicationYear "2009" @default.
• W2324254509 type Work @default.
• W2324254509 sameAs 2324254509 @default.
• W2324254509 citedByCount "0" @default.
• W2324254509 crossrefType "journal-article" @default.
• W2324254509 hasAuthorship W2324254509A5016124900 @default.
• W2324254509 hasAuthorship W2324254509A5021513092 @default.
• W2324254509 hasAuthorship W2324254509A5026444533 @default.
• W2324254509 hasAuthorship W2324254509A5045568688 @default.
• W2324254509 hasConcept C126322002 @default.
• W2324254509 hasConcept C185592680 @default.
• W2324254509 hasConcept C190283241 @default.
• W2324254509 hasConcept C197934379 @default.
• W2324254509 hasConcept C2776768464 @default.
• W2324254509 hasConcept C2777761686 @default.
• W2324254509 hasConcept C2777938653 @default.
• W2324254509 hasConcept C2778461978 @default.
• W2324254509 hasConcept C2778488018 @default.
• W2324254509 hasConcept C55493867 @default.
• W2324254509 hasConcept C71924100 @default.
• W2324254509 hasConcept C90924648 @default.
• W2324254509 hasConceptScore W2324254509C126322002 @default.
• W2324254509 hasConceptScore W2324254509C185592680 @default.
• W2324254509 hasConceptScore W2324254509C190283241 @default.
• W2324254509 hasConceptScore W2324254509C197934379 @default.
• W2324254509 hasConceptScore W2324254509C2776768464 @default.
• W2324254509 hasConceptScore W2324254509C2777761686 @default.
• W2324254509 hasConceptScore W2324254509C2777938653 @default.
• W2324254509 hasConceptScore W2324254509C2778461978 @default.
• W2324254509 hasConceptScore W2324254509C2778488018 @default.
• W2324254509 hasConceptScore W2324254509C55493867 @default.
• W2324254509 hasConceptScore W2324254509C71924100 @default.
• W2324254509 hasConceptScore W2324254509C90924648 @default.
• W2324254509 hasIssue "15_suppl" @default.
• W2324254509 hasLocation W23242545091 @default.
• W2324254509 hasOpenAccess W2324254509 @default.
• W2324254509 hasPrimaryLocation W23242545091 @default.
• W2324254509 hasRelatedWork W1546234834 @default.
• W2324254509 hasRelatedWork W17488461 @default.
• W2324254509 hasRelatedWork W1965030819 @default.
• W2324254509 hasRelatedWork W2033830377 @default.
• W2324254509 hasRelatedWork W2059755195 @default.
• W2324254509 hasRelatedWork W2065770266 @default.
• W2324254509 hasRelatedWork W2120101496 @default.
• W2324254509 hasRelatedWork W2391935759 @default.
• W2324254509 hasRelatedWork W253925900 @default.
• W2324254509 hasRelatedWork W38805006 @default.
• W2324254509 hasVolume "27" @default.
• W2324254509 isParatext "false" @default.
• W2324254509 isRetracted "false" @default.
• W2324254509 magId "2324254509" @default.
• W2324254509 workType "article" @default.